Specific preclinical liquid ventilator (Inolivent) is currently under joint development in Canada and France. The main application of this liquid ventilator is the ultra-fast induction of therapeutic hypothermia after cardiac arrest. This has been demonstrated to be more protective than slower cooling method after experimental cardiac arrest.
